Slide 1: 2025 Annual Report & Earnings Call
BIOLARGO, INC. oTcax: BGO 2025 Annual Report & Earnings Call Commitments Made & Commitments Delivered
Slide 2: Safe Harbor Statement
Safe Harbor Statement All statements, other than statements of historical fact, included in this presentation regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, and plans and objectives of management are forward-looking statements. Thes
Slide 3: Disciplined Execution: Hitting Critical Milestones
| Disciplined Execution Hitting Critical Milestones AT WE SAID wE*D DO wma ve 01 | ins acc at municpa ste | © rec ntti at tate sock, Ny son 2026 | Lean ye Medical commercially | © Fest stocking orer eceived& shipped Feb 2026) | present clinical data for vieCLYR™ Jo Exceptional results at Boswick Sym
Slide 4: The BioLargo Impact Portfolio — Sum of the Parts
| The BioLargo Impact Portfolio — Sum of the Parts Four Platforms. Four Massive Markets. One Company. Clyra Medical Advanced Wound Care & Infection Control, FDA cleared ViaCLYR™ technology. 48% + 6% Royalty e Cellinity Battery Liquid Sodium Long-Duration Storage. High density, non-flammable, earth-a
Slide 5: Clyra Medical — First Commercial Revenue
| Clyra Medical — First Commercial Revenue FDA Cleared Formulation. First Order Shipped and Paid. 2025-2026 Commercial jestones Exclusive agreement with Advanced Solution plus a second global 4 >99:9999% antimicrobial kil ate (broad spectrum) distributor preparing for launch. (6,100+ hospitals, 6,30
Slide 6: Clyra Medical — Clinical Validation
| Clyra Medical — Clinical Validation What the Data Shows (Boswick Symposium, Jan 2026) Key Clinical Findings. {© Rapid reduction in wound fluid discharge Noticeable i early in ease in healing activity ment Rapid closure of wound tunnels — a particularly challenging complication tively 7 Dramatic wo
Slide 7: AEC Water Treatment — Solving the PFAS Crisis
AEC Water Treatment — Solving the PFAS Crisis A. The Problem PEAS Crore, Cheraicn) contention afte a Lake Stockholm, NJ Installation 4 The Solution: BioLargo AEC ‘Treats Al PAS: Minimal Waste ‘Scalable: Modular design fits municipal and industrial site ‘Commercial Pipeline:
Slide 8: Cellinity Battery — The Energy Storage Opportunity
| Cellinity Battery — The Energy Storage Opportunity Independent Third-Party Evaluation by U.S. BESS Corp Validates Key Performance Claims wr Giobalstonge demand growing om 200 Gwto & ‘Se Terawatts by 2050 xed nolan seater Gy getsht ony tm hin dependent ele bs ‘Why Cellini is Different Energy Densit
Slide 9: ONM Environmental — Terminated License & New Direction
ONM Environmental - Market Validated Technology, Terminated License & New Direction Proven large-scale commercial success The Path Forward v cn 9 6 mer p + n Commercial Success v one : + 8¢ million units sold in the marketpla Y Pend + $57M+ annual run rate achieved t product launch partner + $13.7M
Slide 10: 2025 Financial Summary
| 2025 Financial Summary The Numbers in Context nETRIC Revenue 2025 s77™ s1.7™ ($15.19) $3.88M $1.53M 2024 s17.78M 930M (435m) $3.55M 36.06M KEY DRIVER Poor ig reves ©. The "Pooph Effect” Revenue post Pooph tect gromngbave business, uated by the licensing depute Ciyra investment i a detberate valsec
Slide 11: 2026 Outlook — The Target Inflection Points
| 2026 Outlook — The Target Inflection Points Multiple Catalysts Converging @ Clyra Medical © Commercial rollout of ViaCLYR™ through Advanced ‘Solutions national network ‘© Additional KOL presentations ‘and clinical publications throughout 2026 ‘© Expanding product portfolio. ‘and revenue (surgical,
Slide 12: Why BioLargo Now?
Why BioLargo Now? The Investment: What Has Changed 4g Commercial Revenue gy Rea Wort vatcation eo _ Battery Technology De-Risked Capital to Execute Dennis P, Calvert | President & CEO